Swedish study adds to data linking GSK vax to narcolepsy

The Swedish regulator has added to evidence linking GlaxoSmithKline's ($GSK) swine flu vaccine to narcolepsy in a registry study of 5.8 million people. A three-fold increased risk of having narcolepsy was seen in vaccinated people under the age of 20. The increase in risk is lower than in some other studies, including a smaller Swedish registry project. Study

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.